News summary

Life Biosciences Announces First-in-Human Phase 1 Trial Data

Source: Lifespan.io • Published: 27 Oct 2026, 15:07

Summarized by Masters of Longevity from Lifespan.io.

Single intravitreal ER-100 plus oral doxycycline was well-tolerated through Day 56.

Life Biosciences Announces First-in-Human Phase 1 Trial Data
Key Takeaways
  • Three OAG participants tolerated Dose Level 1 through Day 56.
  • No dose-limiting toxicities or serious adverse events were reported.
  • Two of three participants showed Humphrey visual field improvements.
Read the full article at Lifespan.io ↗

Continue exploring

Recommended MoL Picks

MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickFrom Metrics to Better LivingEverstride’s May 2026 Consumer Health Market Briefing shows a wellness market moving from products to systems, from tracking to guidance, and from optimization to meaning. The next winners in longevity may not be the companies that measure the most. They may be the ones that help consumers translate health data into a life they actually want to live.